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INTRODUCTION
Cervical cancer is the third largest cancer in the
world, and fortunately, it is the only cancer that
could be detected early. Thus, we can prevent this
cancer from progressing. It is the third most
frequent type of cancer and declared as the fourth
most common cause of deaths from cancer in
women world wide. In 2008, it is estimated that
approximately 530,232 women were diagnosed
with cancer, and 275,008 of them died.1 The
majority of cervical cancers (85%) occur in
developing countries, including Indonesia. The
prevalence of women with cervical cancer in
Indonesia is quite high. Every day, 40-45 new cases
are identified, with the number of deaths reached
20-25 people. In addition, the number of women
at the highest risk states is 48 million people.2 The
Department of Health in South Sulawesi reported
that the highest incidence of breast cancer and
cervical cancer patients were observed in
Makassar, Gowa, Wajo, Bone and Luwu Utara.
In 2009, 97 cases of cervical cancer were detected
in hospitals and 177 in primary health care centers
in South Sulawesi.
Abstract
Objective: To determine the sensitivity and specificity of self-
administered Human Papilloma virus (HPV) test in detecting
pre-cancerous lesions and high degree cervical cancer.
Methods: A case control study design was used in this study. This
study was conducted at Dr. Wahidin Sudirohusodo Hospital and its
affiliate hospitals during the period of October 2014 to May 2015.
Measurement data using HPV self test grant from the Dutch School
Netherlands, Evalyn Brush. Collecting data used questionnaires
before and after doing HPV self test. Laboratory tests are carried out
in Kalbe Genomic using HPV Genotyping capable detect 35 types of
the HPV virus.
Results: A total of 101 subjects were involved in this study. The
subjects were divided into two groups, the case and the controls
(n = 50/51). Level of sensitivity and specificity were obtained for
HPV self test (56% vs 98%). The level of acceptance of new tests
by 62.37% (63 out of 101 respondents) of them admitted that the
new test is simple / easy enough to do. The acuracy rate of diag-
nostic test of this examination is 79%.
Conclusion: Self-administered HPV test could be used as an alter-
native or primary screening for cervical cancer.
[Indones J Obstet Gynecol 2017; 5-3: 173-179]
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Abstrak
Tujuan: Mengetahui nilai sensitivitas dan spesifisitas pemerik-
saan mandiri human papilloma virus (HPV) dalam mendeteksilesi pre kanker derajat tinggi dan kanker serviks.
Metode: Merupakan penelitian analitik case control, single center diRS Dr. Wahidin Sudirohusodo dan Afiliasinya pada bulan Oktober
2014-Mei 2015. Pengumpulan data menggunakan kuesioner sebelum
dan setelah melakukan pemeriksaan HPV mandiri. Pemeriksaan labo-ratorium dilakukan di Kalbe Genomic dengan menggunakan cara
HPV Genotyping yang mampu mendeteksi 35 tipe virus HPV.
Hasil: Penelitian menunjukkan keseluruhan responden berjumlah
101 orang, terbagi menjadi kelompok sakit dan sehat (n=50/51).Tingkat sensitivitas dan spesifisitas yang didapatkan untuk HPV
Mandiri (56% vs 98%). Tingkat penerimaan pemeriksaan baru
sebesar 62,37% (63 dari 101 responden) di antaranya mengakuibahwa pemeriksaan baru ini mudah/cukup mudah untuk dilaku-
kan. Tingkat akurasi uji diagnosis pemeriksaan ini didapatkansebesar 79%.
Kesimpulan: Pemeriksaan HPV mandiri dapat digunakan sebagaialat pemeriksaan alternatif atau skrining primer pada kanker serviks.
[Maj Obstet Ginekol Indones 2017; 5-3: 173-179]
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Although cervical cancer is frequently found in
women above 50 years, it is more often found in
reproductive aged women in developing countries.
In several countries where good screening pro-
gram do not exist, cervical cancer patients often
come lately with an advanced stage, and most of
the patients can not be cured.3 HPV (Human Papi-
llomavirus) infection of the cervix is an important
event for the occurrence of cervical cancer. It is
estimated that 50-80% of sexually active women
will become infected with HPV in their lives. The
existence of persistent HPV infection is one of the
predisposing factors of dysplasia and cervical
cancer. HPV 16 and 18 are the main causes of this
cancer and found in 70% of cases of cervical cancer
in the world. The sequential plot from being
infected with HPV to having cervical cancer takes
a long time, which is approximately 10 to 20 years.
However, HPV infection is often asymptomatic that
the majority of the patients do not realize that they
are being infected. The infection they may progress
to pre-cancerous stage, which is also frequently
asymptomatic. It begin with the change of normal
cells into pre-cancerous cells and then into cancer
cells (dysplasia).4
Visual inspection with acetate (VIA) or with
Lugol’s iodine (VILI) is an alternative of the
cytology and HPV laboratory tests. These
examinations use visual observation without
magnification to detect pre-cancerous lesions on
the cervical columnar squamous junction.
According to various studies, both test had a
sensitivity of 55-85%, and the specificity for each
test was 49-86% for VIA and 73-93% for VILI.
These tests are suitable for developing countries,
since both of these test do not require complex
laboratory equipments. Moreover, the time needed
to train health workers to conduct these tests is
relatively short. This examination is used as an
initial screening method for cervical cancer due to
its low cost. A cervical cancer prevention program
named ’see and treat’, a one day sevice where a
woman would undergo VIA or VILI test followed
with cryotherapy, has been proven to effectively
reduce the incidence of high-grade precancerous
lesions and cervical cancer in developing
countries.5
Cytology is often constrained by the powerless-
ness of sufficient infrastructure, especially in
developing countries. Thus, there are only few
women who can get access to screening or initial
treatment programs. Alliance for Cervical Cancer
Prevention has seeked some alternatives such as
cytology, VIA, and HPV DNA test.3
The high level of sensitivity of HPV DNA tests
may lead to high negative predictive value, even
against the precursor of adenocarcinoma, which is
often not detected by cytology.6 HPV test has a
higher level of sensitivity in detecting high-grade
precancerous lesions, and the positive predictive
value is higher due to high incidence of cervical
cancer in developing countries. The effectiveness
of cervical cancer screening programs can be
increased by using self-administered HPV test.
Self-administered HPV test is globally acceptable
and has been shown to increase patients’
obedience and rate of screening coverage despite
existence of overcoming sociocultural barriers in
developing countries.7 This study is aimed to
determine the sensitivity and specificity of self-
administered HPV test indetecting the high degree
precancerous lesions and cervical cancer, as well
as the acceptance of self-administered HPV test on
high degree precancerous lesions and cervical
cancer. We hope this test could an alternative
screening tool for detecting high degree pre-
cancerous lesions and cervical cancer.
METHODS
A case control study design was used. Samples
were taken from October 2014 until May 2015 at
several teaching hospitals where were connected
to Department of Obstetrics and Gynecology,
Faculty of Medicine Universitas Hasanuddin,
Makassar, such as RSUP Dr. Wahidin Sudiro-
husodo and other network hospitals.
Subjects were sexually active women aged 20-
55 years who had undergone Pap smear tests at
the laboratory of Anatomic Pathology and several
teaching hospitals in Makassar. The inclusion
criteria were sexually women aged 20-55 years,
sexually active, normal Pap smear results in the
last 3 months, the abnormal results of Pap smear
and or biopsy in the last 3 months. While the
exclusion criteria are recently menstruation within
1 week, were using drugs in the form of ovules, are
pregnant, have undergone radiation to the pelvic
area, had undergone surgical removal of the
uterus. This study was approved by the Ethics
Committee for Biomedical Research In Humans at
the Faculty of Medicine Universitas Hasanuddin,
Makassar.
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The data were collected by means of a question-
naire. Subjects were asked to fill out a question-
naire. They were accompanied by a research assis-
tant. Subjects were asked regarding his willingness
to participate in the study. If they agreed to be
participants, we would give them explanations
both by verbal and written through leaflets about
the self-administered HPV test. After giving a brief
explanation and informed consent, we asked the
subjects to wash their hands and go to the cubicles.
Subsequently, the subjects would perform the self-
administerd HPV test. Specimens derived from the
tests were incorporated into a sterile tube
containing solution of 1 ml Phosphate Buffered
Saline (PBS) and vortexed during 3x15 seconds.
Consequently, 0.5ml of each sample was used for
the extraction of nucleic acids and the remaining
would be stored in a freezer at a freezing rate of
-20° C. Extraction, detection and genotyping of HPV
were performed using MY09/11 PCRat the Kalbe
Genomic laboratory and conducted according to
the standard protocol. The assay was done by using
automated DNA extraction, DNA amplification
using PCR, and detection of high risk HPV geno-
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, and 68) and low risk HPV genotypes (6, 11,
42, 43, 44, and 81). The entire negative results that
were found rid of the presence of types of HPV
above at a level of 50 IU.8
The total subjects in this study were 91 patients.
Of these, 50 were categorized as abnormal, while
the others were categorized as normal. Data
analysis using SPSS 18, 2x2 tables can be used to
assess the sensitivity and specificity of HPV Self
test and then we concluded the hypothesis test
using 2 times trial for the interpretation of
diagnostic test results. P value < 0.05 was
considered significantly available.
RESULTS
The majority of the subjects were in the 40-49 age
group, had graduated from high school, worked as
housewives, were multiparous, did not use
contraceptive methods, complained of vaginal
discharge, did not know about cancer screening.
(Table 1). According to biopsy results, the majority
of the abnormal group had perform CIN II in the
amount of 85.7%. In addition, based on pap smear
result, the majority of the normal group has
perform Follicular servisitis as many as 24
respondents (100%).
Table 1. Characteristics of the Subjects
Characteristics Abnormal (n=50) Normal (n=51) TOTAL (n=101)
N % N % N %
Age (year)
20-29 3 17.6 14 82.4 17 100
30-39 15 45.5 18 54.5 33 100
40-49 22 53.7 19 46.3 41 100
> 50 10 100 0 0 10 100
Educational status
No educational/primary 2 50.0 2 50.0 4 100
Primary school graduates 2 33.3 4 66.7 6 100
Junior high school graduates 6 46.2 7 53.8 13 100
Senior high school graduates 20 40.0 30 60.0 50 100
Scholars 20 71.4 8 28.6 28 100
Occupation
Company employees/civil servants 18 78.3 5 21.7 23 100
Self employer 2 50.0 2 50.0 4 100
Housewife 30 40.5 44 59.9 74 100
Parity
Nulliparous 9 75.0 3 25.0 12 100
Multiparous 41 46.1 48 53.9 89 100
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Distribution of the Subjects
63 subjects felt easy to perform self-administered
HPV test (60.3% in abnormal group and 39.7% of
normal group). 92 subject did not experience any
problems or symptoms during or following the
self-administered HPV test (54.3% in abnormal
group and 45.7% in normal), however, there were
5 subject who experienced pain. One subject re-
ported bleeding and 2 subejcts’ devices were put
off spontaneously. Approximately 89 subjects still
wanted to repeat self-administered HPV test due
to the ease of test (56% of abnormal group and
44% of normal). 12 subjects did not want to repeat
self-administered HPV test due to pain and no spe-
cific reason (100% of the normal group). There
were 63 subjects that liked the self-administered
HPV test ( 60.3% of abnormal group and 39.7% of
normal), and there were 10 subjects prefer the Pap
smear test (20% of abnormal group and 80% of
normal).
Characteristics Abnormal (n=50) Normal (n=51) TOTAL (n=101)
N % N % N %
History of contraception
Never use 31 53.4 27 46.6 58 100
Condom 2 50.0 2 50.0 4 100
Pil 6 60.0 4 40.0 10 100
Injection 10 37.0 17 63.0 27 100
IUD 0 0 1 100 1 100
Tubectomy 1 100 0 0 1 100
Symptoms
No symptoms 0 0 24 100 24 100
Vaginal discharge 26 56.5 20 43.5 46 100
Abnormal bleeding 14 93.3 2 6.7 15 100
Postcoital bleeding 9 75.0 3 25.0 12 100
Lower abdominal pain 1 50.0 1 50.0 2 100
Pruritus 0 0 2 100 2 100
Knowledge about Screening
Do not know 43 53.8 37 46.2 80 100
Conventional Pap Smear 7 33.3 14 66.7 21 100
Histopathological results
Biopsy
CIN II 12 85.7 2 14.3 14 100
CIN III 7 100 0 0 7 100
Adenocarcinoma 8 100 0 0 8 100
Squamous Cell Carcinoma 23 1000 0 0 23 100
Pap Smear
Normal 0 0 10 100 10 100
Follicular cervicitis 0 0 24 100 24 100
Bacterial Vaginosis 0 0 1 100 1 100
Candidiasis 0 0 6 100 6 100
Gardanella infection 0 0 7 100 7 100
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Table 2. Distribution of Subject Regarding Self-administered HPV Test Acceptability Based On Patients’ Characteristic.
Subjects’acceptability of the self­
administered HPV test
Easy (n=63) Difficult (n=38) TOTAL (n=101)
N % N % N %
Age (years)
20-29 7 41.2 10 58.8 17 100
30-39 22 66.7 11 33.3 33 100
40-49 27 65.9 14 34.1 41 100
> 50 7 70.0 3 30.0 10 100
Educational status
No educational/primary 0 0 4 100 4 100
Primary school graduates 2 33.3 4 66.7 6 100
Junior high school graduates 11 84.6 2 15.4 13 100
Senior high school graduates 32 64.0 18 36.0 50 100
Scholars 18 64.3 10 35.7 28 100
Occupation
Company employees/civil servants 17 73.9 6 26.1 23 100
Self employer 3 75.0 1 25.0 3 100
Housewife 43 58.2 31 41.9 74 100
Parity
Nulliparous 5 41.7 7 58.3 12 100
Multiparous 58 65.2 31 34.8 89 100
History of contraception
No use 33 56.9 25 43.1 58 100
Condom 3 75.0 1 25.0 4 100
Pil 8 80.0 2 20.0 10 100
Injection 17 63.0 10 37.0 27 100
IUD 1 100 0 0 1 100
Tubectomy 1 100 0 0 1 100
Symptoms
No symptoms 17 70.8 7 29.2 24 100
Vaginal discharge/Fluor albus 23 50.0 23 50.0 46 100
Abnormal bleeding 15 100 0 0 15 100
Postcoital bleeding 6 50.0 6 50.0 12 100
Lower abdominal pain 1 50.0 1 50.0 2 100
Pruritus 1 50.0 2 50.0 2 100
Knowledge about Screening
Do not know 53 66.2 27 33.8 80 100
Conventional Pap Smear 10 47.6 11 52.4 21 100
Table 3. The Result of Self-administered HPV Test as a Diagnostic Test in Identifying Pre-cancerous Lesion and Cervical Can-
cer.
Self­administered
HPV test
Histopathological Results
Abnormal Normal Total p Value
N % N % N %
Abnormal 28 96.6 1 3.4 29 100 0.000
Normal 22 30.6 50 69.4 72 100
TOTAL 50 50 51 50 101 100
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The self-administered HPV test for detecting
high degree of precancerous lesions and cervical
cancer had a sensitivity of 56% and a specificity of
98% (Table 3).
DISCUSSION
Self-administered HPV has a sensitivity and spe-
cificity of 56% and 98%. In our study, the ability
of self-administered HPV test to ensure positive
results is up to 96%. However, using this test for
screening is not recommended, because screening
requires a high negative predictive value.
Previous researchers set an age limit of 20 years
based on the pathogenesis of the disease, some
women who are sexually active at a young age will
give a positive HPV test results. However,
approximately 70% newly infected young women
with HPV would be free of infection after 12
months. Meanwhile, an age limit of 55 years was
approved due to the effectiveness of VIA test
known to decline in older age groups, and
become 20% in women aged above 55 years.
These criteria are based on the manifestation
histologically of low-grade changes (CIN1) on new
infections with high risk type of HPV. These
changes are usually temporary, whereas in CIN2/3
are more like a precursor to cervical cancer. High
degree lesions CIN2/3, along with several risk
factors would increase the incidence of persistent
high-risk HPV infections. In addition, the latest
pap smear test (during the last 3 months) and
histopathological diagnosis using biopsy are the
last enforcement and the gold standard throughout
the examination. This would have a direct impact
on the results of diagnostic tests performed.9
In this study, we found only 5.94% (6 of 101)
subjects complained pain symptoms. There were
no subjects that constrained shame/shy to do the
test. Constraints related to the examination device
feature are also found in this study, there were two
respondents who had to re-examination due to the
testing vaginal brush on the device is taken off and
left inside the vagina. This caused discomfort
among respondents, and this was one of the
negative outcomes that was found in terms of the
integrity of the device so that the study was
expected to have an impact on the design and
plan to use the device properly. Pain and shame
is not a problem in the population in Italy.10
In our study, the self-administered HPV test had
a sensitivity level of 56% and a specificity of 98%
in detecting HPV in a high degree of precancerous
lesions and cervical cancer. These results indicate
that screening is only able to detect 56% of the
abnormal group, and if the result is negative, we
could ensure the absence of disease is up to 98%.
The accuracy of this diagnostic test is up to 79%.
These results indicate that 79% of the tests that
carried out have compatibility with the gold
standards from the results of the whole sample. In
brief, we could say that if a person is diagnosed
negatively with self-administered HPV test, the
probability to get a negative result in histopatho-
logy finding is 98%. Based on previous studies,
high risk HPV DNA can identify 99.7% of cervical
cancers and 95% of high-grade precancerous
lesions.11
The results of this study was different compared
the previous studies. The high risk type of HPV was
only identified up to 50% (n = 16/32) of cervical
cancers and 31.57% (n = 6/19) of high-grade
precancerous lesions. The sensitivity of HPV
DNA tests for the detection of CIN2+ was still
better than cytology (94% vs 65%).11
CONCLUSIONS
Self-administered HPV test could be used as an
alternative or primary screening for cervical
cancer.
SUGGESTIONS
Government health programs should focus on pre-
vention of cervical cancer. In addition, they should
include an integrated national screening program.
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